MBX.TO - Microbix Biosystems Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.2650
+0.0250 (+10.42%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.2400
Open0.2450
Bid0.2400 x 0
Ask0.2650 x 0
Day's Range0.2400 - 0.2650
52 Week Range0.1700 - 0.3900
Volume376,900
Avg. Volume163,942
Market Cap28.818M
Beta (5Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)-0.0050
Earnings DateFeb 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 01, 1999
1y Target EstN/A
  • GlobeNewswire

    Microbix Announces Annual and Special Meeting Voting Results

    MISSISSAUGA, Ontario, April 01, 2020 -- Microbix Biosystems Inc. (TSX: MBX, “Microbix®” or the “Company”), a life sciences innovator making critical ingredients that enable the.

  • GlobeNewswire

    Microbix Creates Quality Assessment Product for COVID-19 Tests

    MISSISSAUGA, Ontario, March 30, 2020 -- Microbix Biosystems Inc. (TSX: MBX, Microbix®) announces the creation, verification, and imminent commercial availability of a quality.

  • GlobeNewswire

    Microbix Annual General Meeting Process Update

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, provides an update about its Annual General Meeting (“AGM”). Due to the COVID-19 pandemic, Microbix also wants to avoid the need for in-person attendees at this year’s AGM, a goal enabled by setting-up an online link to allow shareholders to listen to the AGM and view a CEO presentation. Microbix will also provide a teleconference number, so that shareholders without up-to-date computer access can listen-in by telephone.

  • GlobeNewswire

    Microbix Announces Quality Products Distribution Agreement

    Microbix Biosystems Inc. (TSX: MBX, Microbix®),  a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the appointment of The Medical Supply Company of Ireland (MSC) as a distributor. Under an agreement between the parties, MSC has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for the Republic of Ireland and Northern Ireland.

  • GlobeNewswire

    Microbix Announces Issuance of Stock Options

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. In consultation with the CEO and CFO, the Microbix Board of Directors has approved the issuance of 2,200,000 options in accordance with the terms of the Stock Option Plan.

  • Should You Take Comfort From Insider Transactions At Microbix Biosystems Inc. (TSE:MBX)?
    Simply Wall St.

    Should You Take Comfort From Insider Transactions At Microbix Biosystems Inc. (TSE:MBX)?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswire

    Microbix Reports Results for Q1 Fiscal 2020

    MISSISSAUGA, Ontario, Feb. 13, 2020 -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of.

  • GlobeNewswire

    Microbix Completes Non-Brokered Private Placement of $2.3 million

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units (“Units”) at a price of $0.20 per Unit. Each Unit consists of one common share (“Common Share”) of Microbix and one warrant (“Warrant”) to purchase one Common Share.

  • GlobeNewswire

    Microbix Reports Results for Fiscal 2019

    MISSISSAUGA, Ontario, Dec. 20, 2019 -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of.

  • GlobeNewswire

    Microbix Invited to Present Product Results at HPV Congress

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces it has been invited to present the performance of its in-vitro diagnostics (IVD) quality products “IVD Controls” at EUROGIN 2019, the annual congress of the European Research Organization on Genital Infection & Neoplasia. At EUROGIN, Microbix will be exhibiting alongside leading IVD and pharmaceutical companies working on prevention and detection of Human Papilloma Virus (HPV) infection.

  • GlobeNewswire

    Microbix Wins Ontario Business Award

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices (QAPs™) that help ensure test accuracy, announces it has been awarded the “Beyond Borders” Ontario Business Achievement Award (OBAA) for 2019 by the Ontario Chamber of Commerce (OCC). The award was presented at the OCC OBAA gala the evening of November 14 and recognizes success in developing and implementing innovative export strategies that positively drive its business. Microbix was also runner-up in OCC’s “Excellence in Innovation” category.

  • Those Who Purchased Microbix Biosystems (TSE:MBX) Shares Five Years Ago Have A 65% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Microbix Biosystems (TSE:MBX) Shares Five Years Ago Have A 65% Loss To Show For It

    We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...

  • GlobeNewswire

    Microbix Presenting Product Results at Industry Conference

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and quality control medical devices, announces it is making two presentations about the performance of its in-vitro diagnostics quality products (IVD Controls) at the 11th European Meeting on Molecular Diagnostics (EMMD) in Noordwijk, The Netherlands, October 9-11, 2019.

  • GlobeNewswire

    Microbix Presenting at StableView TECH19 Conference

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and quality control medical devices, announces that it will be presenting to investors about Microbix at the StableView TECH19 conference, organized by StableView Asset Management and being held at the Arcadian Court event venue in Toronto, ON, October 3, 2019. Microbix’s CEO, Cameron Groome, will make a corporate presentation and, with COO Ken Hughes and CFO Jim Currie, will undertake a series of one-on-one meetings with growth company investors during the conference.

  • GlobeNewswire

    Microbix Presenting at Muskoka Capital Conference

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and medical devices for test quality control, announces that it will be presenting to investors about Microbix at the Muskoka Capital Conference, organized by Capital Event Conferences and being held at the JW Marriott Rosseau Muskoka, in Minett, ON, September 27-29, 2019. Microbix’s CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the conference.

  • GlobeNewswire

    Microbix Quality Products Enter U.S. Market

    HPV is a family of more than 100 closely-related viruses, commonly described as “types,” of which one or more are carried by most sexually-active adults.  Over a dozen HPV types have been linked to development of cancers and are therefore classified as high-risk. Infections with high-risk HPV types are leading causes of cervical, penile, anal, oral, and throat cancers.  Cervical cancer screening has historically relied on pathology-based testing (i.e., the “PAP” test), but no such program exists for other HPV-driven cancers.  Additionally, reliance on the newer technology of nucleic acid (NA) HPV testing is hampered by a lack of fully-adequate sample controls to help ensure accurate positive or negative test results.  Microbix’s IVD control products aim to address that need by supporting the tens of millions of HPV tests already conducted annually in the United States and helping to enable greater usage of such testing.

  • Does Microbix Biosystems (TSE:MBX) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Microbix Biosystems (TSE:MBX) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    Microbix Reports Results for Q3 Fiscal 2019

    TORONTO, Aug. 12, 2019 -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its third quarter and nine.

  • GlobeNewswire

    Microbix Provides Bioreactor Update

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on the conversion of its highest-selling product into bioreactors – that the largest customer for that antigen has confirmed its intended timetable for conversion of its future orders to bioreactor product and has provided its initial full-scale order. In 2018, Microbix completed a 500% expansion of its bioreactor capacity, moving to six full-scale units from one, along with multiple other production facilities upgrades. Its facilities upgrades were made to house up to eight bioreactors in a dedicated suite.

  • GlobeNewswire

    FedDev Ontario Supports New Microbix Facility in Mississauga

    Today, the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, Minister responsible for FedDev Ontario, and Member of Parliament for Mississauga–Malton, announced a FedDev Ontario contribution of $2,752,500 for Microbix to scale-up production at its state-of-the-art antigen manufacturing facilities – among the largest and most efficient operations of their kind. Microbix, a developer and manufacturer of biological and technological solutions for human health and wellbeing, produces antigens for infectious disease diagnostic tests.

  • Do Directors Own Microbix Biosystems Inc. (TSE:MBX) Shares?
    Simply Wall St.

    Do Directors Own Microbix Biosystems Inc. (TSE:MBX) Shares?

    A look at the shareholders of Microbix Biosystems Inc. (TSE:MBX) can tell us which group is most powerful. Generally...

  • GlobeNewswire

    Microbix Reports Results for Q2 Fiscal 2019

    Sales of $4.25 million for Q2 were very strong (up 42% year-over-year) and were principally to antigen customers based in North America and Western Europe. In Q2, Microbix demonstrated strong year-over-year improvement in percentage gross margin (up by 13%) and achieved materially positive net earnings (an improvement of $733,854 versus the prior fiscal year “Q2 2018”).

  • GlobeNewswire

    Microbix to Present at Bloom Burton Conference

    TORONTO, April 29, 2019 -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that its CEO, Cameron Groome, has.

  • GlobeNewswire

    Microbix Announces Management Changes

    Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has appointed Dr. Kenneth (Ken) Hughes as its Chief Operating Officer (“COO”) and that Mrs. Kathryn Froh, its Vice President, Diagnostics is retiring from her full-time role, but will be remaining an employee and will be available to assist with special projects. Ken Hughes has been in the life sciences industry for more than 25 years and has worked as a CEO, senior executive, consultant and corporate director. Ken received his PhD from the University of London (UK) and has previously served as VP of Scientific Affairs at Microbix.

  • How Financially Strong Is Microbix Biosystems Inc. (TSE:MBX)?
    Simply Wall St.

    How Financially Strong Is Microbix Biosystems Inc. (TSE:MBX)?

    While small-cap stocks, such as Microbix Biosystems Inc. (TSE:MBX) with its market cap of CA$24m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a d...